Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to filter the trials based on location, phase of development, tumor genomic alteration, or drug name, category or target
No preference
IL-2R/IL-15R beta/gamma
No preference

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT05092360IIIPlatinum resistant or refractory ovarian cancer that must have had prior bevacizumab (5 or less prior therapies for platinum resistant disease)A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)AL, AK, AZ, CA, FL, IL, IN, KY, LA, MD, MI, NJ, NM, NY, NC, OH, OR, PA, SD, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Nemvaleukin alfaintermediate-affinity interleukin-2 receptor agonist ALKS 4230, Nemvaleukin, ALKS4230IL-2R/IL-15R beta and gamma agonistClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04592653IIRecurrent ovarian cancerClinical and Immunologic Activity of Nemvaleukin Alfa With Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3MI, TX, UT, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Nemvaleukin alfaintermediate-affinity interleukin-2 receptor agonist ALKS 4230, Nemvaleukin, ALKS4230IL-2R/IL-15R beta and gamma agonistClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05824975I/IIaAdvanced solid tumorsAn Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2a Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Therapeutic Activity of GI-102 in Patients With Advanced or Metastatic Solid TumorsAZ, FL, MN, OHView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
GI-102bispecific CD80-lgG4Fc-IL-2v fusion protein GI-102Blocks CTLA-4 interaction with its ligand CD80 and activates IL-2R beta/gamma to increase T cell activation and immune responseClinical Trials
NCT04977453I/IIAdvanced solid tumorsA Phase 1/2 Study to Evaluate Safety, Tolerability, PK, and Therapeutic Activity of GI-101 as a Single Agent and in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Patients With Advanced, Metastatic Solid TumorsNY, NCView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
GI-101bispecific CD80-lgG4Fc-IL-2v fusion protein GI-101Blocks CTLA-4 interaction with its ligand CD80 and activates IL-2R beta/gamma to increase T cell activation and immune responseClinical Trials
LenvatinibMK-7902, Lenvima, ER-203492-00, E7080Multi-targeted RTK inhibitorApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
Radiation TherapyIrradiation, Radiotherapy
NCT04009681I/IIAdvanced solid tumorsAn Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid TumorsAZ, CO, FL, TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
anti-EGFR AbEGFR antagonistClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
SAR444245pegylated recombinant IL-2 variant THOR-707, THOR-707IL-2R/IL-15R beta and gamma agonistClinical Trials
NCT05081609I/IIAdvanced solid tumorsIL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, Standard of Care Chemotherapy, or TransCon TLR7/8 Agonist, or in Combination With Pembrolizumab and Standard of Care Chemotherapy, in Adult Participants With Locally Advanced or Metastatic Solid Tumor MalignanciesMA, NC, OH, PA, TNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
TransCon IL-2 β/γIL-2R/IL-15R beta and gamma agonistClinical Trials
NCT05086692I/IIAdvanced solid tumorsA Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid TumorsCA, FL, GA, MIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MDNA11IL-2R/IL-15R beta and gamma agonistClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05382325IAdvanced solid tumors (inc expansion)A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of MK-1484 as a Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid TumorsSD, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MK-1484IL-2R/IL-15R beta and gamma agonistClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04250155IAdvanced solid tumors (inc expansion)A Phase Ia/Ib, Open-Label, Multicenter, Global, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XmAb24306 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid TumorsCA, CT, TN, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
XmAb24306interleukin-15/interleukin-15 receptor alpha complex-Fc fusion protein XmAb24306, IL15/IL15R alpha heterodimeric Fc-fusionsIL-2R/IL-15R beta and gamma agonistClinical Trials

If you have any questions or would like help with your search, please call us at: 858-657-0282 or email us at patientsupport@clearityfoundation.org.